🔴 Indaptus Therapeutics is trading 6.15% down in pre-market with no confirmed company-specific catalyst

Indaptus Therapeutics is trading 6.15% down at $1.95 after no confirmed company-specific catalyst was identified for September 10, 2026.

• Available coverage reports no recent news for the security.
• Shares gained 51.64% on September 8 and 12.43% on September 9.
• Broader futures are mixed, so macro sentiment does not clearly explain the company-specific pre-market weakness.